Potential therapeutic application of mesenchymal stem cell-derived exosomes in SARS-CoV-2 pneumonia

Ali Akbari and Jafar Rezaie*

Abstract

Background: The outbreak of a new virus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has now become the main health concern all over the world. Since effective antiviral treatments have not been developed until now, SARS-CoV-2 is severely affecting countries and territories around the world.

Methods: At the present review, articles in PubMed were searched with the following terms: mesenchymal stem cells, exosomes, coronavirus, and SARS-CoV-2, either alone or in a combination form. The most relevant selected functions were mesenchymal stem cell-derived exosomes and SARS-CoV-2 virus infection.

Results: SARS-CoV-2 could damage pulmonary cells and induce secretion of different types of inflammatory cytokines. In the following, these cytokines trigger inflammation that damages the lungs and results in lethal acute respiratory distress syndrome (ARDS). The main characteristic of ARDS is the onset of inflammation in pulmonary, hyaline formation, pulmonary fibrosis, and edema. Mesenchymal stem cell-derived exosomes (MSC-Exo) are believed to have anti-inflammatory effects and immune-modulating capacity as well as the ability to induce tissue regeneration, suggesting a significant therapeutic opportunity that could be used to SARS-CoV-2 pneumonia treatment. Besides, exosomes may serve as a biomarker, drug delivery system, and vaccine for the management of the patient with SARS-CoV-2.

Conclusion: MSC-Exo may serve as a promising tool in the treatment of SARS-CoV-2 pneumonia. However, further work needs to be carried out to confirm the efficacy of exosomes in the treatment of SARS-CoV-2 pneumonia.

Keywords: Virus pneumonia, Mesenchymal stem cells, Exosomes, SARS-CoV-2

Background

The exploration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the city of Wuhan in China is done in December 2019. SARS-CoV-2 can transmit human to human and spread rapidly to other parts of China and then to other countries. The number of individuals with SARS-CoV-2 has rapidly increased in a few weeks; as of 8 July 2020, more than 11 million cases have been reported across 213 countries and territories, resulting in more than 500,000 deaths, and more than 4 million people have recovered [1]. The World Health Organization (WHO) recognized it on January 12 and named it “new novel coronavirus 2019 (2019-nCoV)”; therefore, coronavirus 2019 (2019-nCoV) and COVID-19 virus are stated as follows: 2019-nCoV is a common name, and SARS-CoV-2 is a classification name for this new emerging virus. Because of the increasing afflicted people, concerns about reserve restrictions, and emerging understanding on how to best treat SARS-CoV-2, healthcare systems have established

* Correspondence: J.rezaie88@gmail.com
Solid Tumor Research Center, Cellular and Molecular Medicine Research Institute, Urmia University of Medical Sciences, Shafa St, Ershad Blvd., P.O. Box: 1138, Urmia 57147, Iran

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
minimal therapeutic cares for both hospital admission and mechanical ventilation [2]. Currently, there is a significant lack of antiviral agents that could be used specifically for the treatment of SARS-CoV-2 infection. Although symptomatic and supportive cares are recommended for severely infected individuals, those with advancing age and co-morbidities such as diabetes and heart diseases remain to be at high risk for adverse outcomes. Therefore, it is urgent to find a safe and effective therapeutic approach to patients with severe SARS-CoV-2 virus characterized by a severe acute respiratory impairment [3]. It was demonstrated that mesenchymal stem cells (MSCs) and their derivatives such as exosomes (MSC-Exo) considerably improved lung inflammation and pathological damage resulting from different types of lung injuries [4, 5]. MSC-Exo have been shown to harbor different proteins and RNAs that have therapeutic effects such as regenerative, anti-inflammatory, pro-angiogenic, immunomodulatory, and anti-fibrotic properties on damaged tissues [6–8]. Based on these pieces of evidence, in this review, we aimed to discuss the possible therapeutic application of exosomes in SARS-CoV-2 virus infection.

Coronaviruses
Coronaviruses are enclosed, sphere-shaped, or pleomorphic viruses, containing single-strand positive-sense RNA genome which is the longest among the RNA viruses [9]. They belong to a large family of virus which is the leading cause of common cold and severe infection such as Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS) [10–12]. Before the recent pandemic, six types of coronavirus species are documented to induce human respiratory diseases [13]. There are four different coronaviruses types, namely NL63, human coronaviruses 229E, HKU1, and OC43, which classically infect only the upper respiratory system and cause fairly light symptoms [14], whereas three other coronaviruses like SARS-CoV, MERS-CoV, and more recently identified SARS-CoV-2 can infect the lower respiratory system and cause pneumonia, which can be lethal. SARS-CoV-2 is a member of the betacoronavirus genus. It genetically resembles, among human coronaviruses, SARS-CoV-2 with 79% similarity [15], while among wholly recognized coronavirus sequences, it has about 98% similarity to bat coronavirus RaTG13 [16] and also share high similarity to coronavirus sequences of pangolin [17].

Pathogenesis of SARS-CoV-2
The affliction of coronaviruses is mediated by a trimeric spike glycoprotein existing on the virion membrane. Similar to the envelope of HIV or hemagglutinin of influenza species, the spike proteins of coronavirus are one of class I fusion proteins [18]. SARS-CoV-2 enters into cells when the S protein binds to the ACE2 receptor located on the host cell membrane [19] (Fig. 1). After docking, the S protein conformation is changed, which facilitates virus entry into the endosomal pathway. Then, viral components such as RNA were uncoated inside the cell and translated into the viral components. Once the structural proteins of SARS-CoV-2 are formed, nucleocapsids initially are assembled in the cytoplasm and then inward bud into the lumen of the endoplasmic reticulum (ER)–Golgi transitional compartments. Then, SARS-CoV-2 structural proteins are released out of the infected cell via exocytosis [19] (Fig. 1). SARS-CoV-2 spreads mostly via respiratory droplets and via, likely, but unconfirmed, the orofecal route. During infection, the average latency is around 4–5 days earlier before the symptom begins [20–22]; however, 97.5% of the symptoms emerge within 11.5 days [22]. The results reported from hospitals indicate patients with SARS-CoV-2 basically show fever, dry cough, muscle and/or joint pain, difficulty in breathing, diarrhea, nausea, headache, and hemoptysis [23–26]. Between days 5 and 6 after the onset of symptoms, SARS-CoV-2 viral load rises to its peak—expressively earlier than that of the SARS-CoV one—so around 10 days later, the viral load peak reaches maximum [27–29]. Within 8–9 days after symptom onset, severe COVID-19 patients develop acute respiratory distress syndrome (ARDS) with aggressive inflammatory responses, hyaline formation, and pulmonary fibrosis [24, 30]. So, disease severity is mostly caused by the immune responses of the host immune system. In addition, the relation between growing severity and age is mostly alike to that of SARS-CoV and MERS-CoV [24, 26]. ARDS caused by SARS-CoV-2 is defined by the struggle in breathing, insufficient blood oxygen level, and also failure in the respiratory system that is responsible for death in 70% of lethal SARS-CoV-2 patients [31]. Some individuals may capitulate to secondary fungal and bacterial infections [26]. Furthermore, inflammatory cytokine storm caused by the immune system causes death (28%) followed by viral infection and/or secondary infections [31]. The majority of patients show mild symptoms; however, some patients develop ARDS likely triggered by a cytokine storm, increased inflammation, septic shock, failure in organs, and blood clots [32, 33]. Interaction between SARS-CoV-2 infection and immune cells leads to dysregulated immune responses and increased risk of multi-organ dysfunction. In SARS-CoV-2-infected individuals, different pro-inflammatory cytokines and other mediators like IL-2, IL-10, IL-7, IL-6, IL-1β, IFNγ, INF-α, monocyte chemoattractant protein-1 (MCP-1), and induced protein 10 (IP10) significantly increased, causing failure in multi-organs [34–36] (Fig. 2). Increased level of cytokines and chemokines...
attracts several immune cells, especially T lymphocytes and monocytes, but not neutrophils, from the circulatory system into the infected tissue [37, 38]. The entry of immune cells into the lung tissue and the influx of lymphocytes into the airways may correlate with the high neutrophil-to-lymphocyte ratio, increased T helper-to-T regulatory cell ratio, and lymphopenia, which are present in approximately 80% of individuals [20, 39]. Furthermore, SARS-CoV-2 virus, which is a cytopathic virus, can induce injury and death in cells and tissues as a consequence of the viral life cycle [40]. Viral infection and replication in epithelial cells of the respiratory system may induce pyroptosis associated with vascular leak, as confirmed in people infected with SARS-CoV [41]. Pyroptosis, a caspase-1-based cell death, is an inflammatory type of programmed cell death that could be prompted by cytopathic viruses [42] and activates inflammatory response [43]. For example, IL-1β as a pyroptosis secretion is increased during SARS-CoV-2 infection [24]. Collectively, in addition to the lesion on pulmonary cells, the cytokine storm triggers inflammatory responses; thus, an increasing effort is focused on the regeneration of damaged cells as well as on the blocking or modulating of inflammatory responses.

**Extracellular vesicles**

Extracellular vesicles (EVs) are heterogeneously bi-phospholipid encapsulated vesicles released from almost all eukaryotic cells, which mediate intercellular communication via transferring different biomaterial components like proteins, different kinds of nucleic acids, lipids, and carbohydrates between cells [44, 45]. Guidelines released by the International Society for Extracellular Vesicles (ISEV, https://www.isev.org) categorize EVs into three subtypes such as exosomes, microvesicles or shedding vesicles, and apoptotic bodies based on their origin and size. In recent years, scientists have a great attention to exosomes due to their pivotal roles in biological systems. Exosomes, 30–120 nm of EVs in size, are originating from endosome compartments (late...
endosomes) located inside the cytoplasm via a complex regularity system [46]. Once secreted, exosomes distribute into the extracellular matrix and bio-fluids and reach the neighboring and distantly located target cells [45]. Exosomes bear different molecules both on their surface and in the lumen. The density of sucrose (1.12–1.18 g/mL) is equivalent to that of exosomes, and they appear as cup-shaped vesicles under an electron microscopy [47]. As exosomes contain active biomolecules from parent cells, they can regulate function, fate, and shapes of target cells, participating in different pathological and physiological conditions [45, 48].

**Role of MSC-derived exosomes in SARS-CoV-2 treatment**

MSCs, multipotent and self-renewal cells, are known as adult stem cells that can be obtained from different tissues such as the adipose tissue, bone marrow, umbilical cord tissue, and amniotic fluid. These cells are capable of differentiation into a variety of cells such as cartilage, bone cells, neural cells, muscle cells, and skin cells [49]. MSCs are widely considered to be the most useful tool in regenerative medicine because these cells can improve damaged tissues and organs via differentiation into different cells and also producing many types of chemokines, cytokines, growth factors, and EVs [50, 51]. MSCs may improve damaged lung tissue through homing toward specific injuries of the lung to maintain homeostasis as well as promote regeneration and secretion of soluble factors and exosomes to moderate inflammation and induce tissue regeneration [52, 53]. More recently, Leng et al. found that the transplantation ofMSCs considerably improved the pulmonary function of patients with 2019-nCoV pneumonia over a period of 2 days [54]. They administered about one million cells per kilogram of weight once and declared that MSCs modulated immune responses, participating in the improvement of the outcome of SARS-CoV-2 pneumonia. Apart from transdifferentiation into tissue cells, the other mechanisms may involve in repairing tissue [55]; alternatively, paracrine effects (such as exosomes) of stem cells are the base of the beneficial effect of cell therapies [56].

According to the literatures, MSC-Exo contain different active biomolecules and can repair and improve myocardial infarcts, kidney injury, CNS diseases, liver cirrhosis, diabetic wound, and lung-associated diseases [57, 58]. The detailed mechanisms involved in exosome-mediated favorable effects and their site of action remain yet unclear. However, reported results from several preclinical non-SARS-CoV-2 models propose that MSC-Exo could also have efficiency against SARS-CoV-2 virus infection. For instance, through the systemic

---

**Fig. 2** Pathogenesis of SARS-CoV-2 virus. During SARS-CoV-2 infection, immune cells produce several pro-inflammatory cytokines. Inflammatory cytokines trigger lethal acute respiratory distress syndrome (ARDS) and failure in multi-organs.
administration, MSC-Exo can modulate immune responses like increased cytokine storms in related acute lung injury and sepsis models [59–64]. Khatri and co-workers found that the administration of MSC-Exo attenuated influenza virus-induced acute lung injury through suppressing influenza virus replication in a pig model [65]. Similarly, a study conducted by Li and colleagues showed that MSC treatment significantly prevents avian H9N2-induced acute lung injury in mice via decreasing the level of chemokines and pro-inflammatory cytokines as well as reducing the infiltration of inflammatory cells onto the lungs [66]. In addition, in *Escherichia coli*-induced pneumonia mouse models, MSC-Exo had the ability to increase phagocytosis of bacteria [61, 67]. It seems that the hallmark of the treatment of SARS-CoV-2 severe pneumonia is to suppress the pro-inflammatory immune response induced by the virus, thus reducing the damage of both alveolar epithelial cells and capillary endothelial cells, followed by the restoring function of lung cells and also the recovery of the lung tissue which may be mediated by MSC-Exo (Fig. 3). Overall, as shown in Fig. 3, the possible therapeutic roles of MSC-Exo in SARS-CoV-2 virus infection may comprise inhibiting pro-inflammatory cytokines, inducing M2 macrophages through delivering PEG2, increasing secretion of anti-inflammatory cytokines like IL-10, and regenerating damaged tissue by producing KGF, VEGF, and HGF [6, 62, 68–71].

By June 2020, the public clinical trial database (https://clinicaltrials.gov) prepared three studies (NCT04276987, NCT0438938, and NCT04384445), and the Chinese Clinical Trial Registry site (ChiCTR, http://www.chictr.org.cn) records two clinical trials (ChiCTR2000030484 and ChiCTR2000030261) aiming to study the inhalation of aerosol and intravenous administration of MSC-Exo in the treatment of severe individuals with SARS-CoV-2 pneumonia. However, for SARS-CoV-2 pneumonia, further studies, which take MSC-Exo into account, will need to be undertaken, because various immune cells respond differently against MSC-Exo and these exosomes may modulate immune responses. For instance, Di Trapani et al. found that MSC-Exo strongly inhibited the function of B cells compared with the function of NK and T cells [72]. Therefore, the immunological activity of MSC-Exo toward different immune cells is dependent on the type of target cell, the cellular maturity, cellular status, and type of diseases among other factors [73, 74]. However, different studies declared that MSC-Exo can inhibit immune cell production and support an immunotolerant microenvironment.

**Other potential therapeutic applications of exosomes in 2019-nCoV treatment**

This section provides some possible application of exosomes in SARS-CoV-2 virus infection treatment; however, there are some limitations regarding their application, which are discussed in the later section. In
addition to exosome therapy, exosomes can serve as a drug delivery system for the treatment of SARS-CoV-2 virus pneumonia (Fig. 3). Exosomes exhibit superiority to other nanocarriers as they are bi-phospholipid vesicles, are of cell origin, safe, and have low immunogenicity and they can pass through the physiological barriers [75]. In this regard, different strategies can be used to construct optional exosomes such as (I) direct engineering method and (II) indirect engineering method [76].

By direct engineering methods, therapeutic agents (bio-molecules and drugs) are directly loaded into exosomes isolated from confident source cells, and then these exosomes are delivered into the tissue of target. By indirect engineering method, parent cells are co-cultured with therapeutic agents or genetically modified to produce artificial/drug-loaded exosomes. Pascucci et al., for instance, demonstrated the capacity of MSCs via microvesicles to package and deliver anti-cancer drugs such as paclitaxel, thus a potential tool for drug delivery. Interestingly, paclitaxel-loaded exosomes exerted a strong anticancer effect compared with exosomes isolated from the control cells [77]. Another possible application of exosomes is using them as a biomarker for SARS-CoV-2 virus infection. For other viruses, exosomes have been shown to transfer viral components such as proteins and miRNAs [78, 79]. Although the detailed mechanism by which SARS-CoV-2 viruses use exosomes for spreading and infection has not been explained exactly, it is reasonable that non-invasive sampling may be a new avenue to monitoring virus infection (Fig. 4). Furthermore, as mention above, exosomes from infected cells contain viral components that make them ideal for vaccine discovery. Although these exosomes could spread infection, a growing body of evidence indicates that the mentioned exosomes can induce immune responses [80]. It was demonstrated that exosomes derived from serum contain antigenic viral protein, suggesting the application of these exosomes as a novel vaccine approach [81]. If viral antigens are transferred on exosomes surface, it likely seems these exosomes serve as a vaccine for the treatment of SARS-CoV-2 virus infection (Fig. 4). Recently, exosomes have been shown to be inhibited both at the biogenesis and uptake level [82, 83]; therefore, inhibition of the biogenesis and secretion of exosomes from infected cells may reduce the speed and development of infection; however, upcoming studies are essential for confirmation. Collectively, in the case of MSC-Exo, the therapeutic application of MSC-Exo in COVID-19 disease may comprise using them as a drug delivery system as well as using them as therapeutic agents for suppressing inflammatory responses and regeneration of damaged tissues.

Challenges
Exosomes have attracted many attentions by both academic and medical industry communities. The existence of different methods for EV isolation, purification, and characterization not only makes big challenges in the result analysis but also causes the conclusions to be unclear in the use of exosomes in clinical trials. Some of the previous studies did not use ISEV guidelines for the characterization of the EVs and assessment of their function, since those experiments have been accomplished prior to the 2014 and 2018 statements of ISEV guidelines of minimal experimental requirements for studies dealt with EVs [84, 85]. Although stem cell-based therapies represent some benefits such as availability and differentiation potential, they have several major hurdles
for therapy [86], which may include (i) determining and targeting a reliable source of cells with phenotypic stability, (ii) the immunological incompatibility that may result in rejection, (iii) difficulty of handling and the higher cost of expansion, and (iv) the potential of cancer risks or formation of ectopic tissue. Exosome therapy exhibits several advantages against cell therapy such as the following: exosomes have a small size, which allows them to pass through filter organs including the liver, spleen, and lungs. Furthermore, as exosomes are bi-phospholipid vesicles, their membrane-binding property imparts excellent biocompatibility and biostability to the loaded cargos and optional drugs, and also, exosomes can pass through biological barriers like the brain-blood barrier. As a hopeful therapeutic tool for novel cell-free therapy, exosomes may serve as an alternative to stem cells in the treatment of various diseases for maintenance of the microenvironment for organ homeostasis and tissue regeneration upon injury [87, 88].

There are great developments in clinical exosome-based studies (https://clinicaltrials.gov); however, until now, no Food and Drug Administration (FDA)-approved exosome products are available (https://www.fda.gov/).

In the case of using MSC-Exo, from a clinical application point of view, a number of concerns should be considered before administering MSC-Exo to SARS-CoV-2-infected people. These comprise the source of MSC-Exo. MSCs, the heterogeneous cells, can be obtained from various tissues, even though MSCs isolated from the same sources may vary in entity and functionality [89, 90]. For example, several donor-derived bone marrow MSCs release exosomes with distinct cytokine profile content [91]. Besides, young MSC-Exo as compared with aged MSC-Exo improved LPS-induced acute lung injury in a mouse model [92]. In addition to immunomodulatory properties, MSC-Exo actually also regulate other biological processes, some with therapeutic functions [93], and others that may induce unexpected non-targeting effects. In order to inhibit the exosome biogenesis and secretion, future attempts should focus on silencing or eliminating exosomes that selectively encourage diseases which are not useful exosomes. Some research groups tried to use exosome inhibitors as versatile tools for exosome biology investigation; however, others have evaluated the inhibitory potential of such drugs in various disease models [82, 94]. Most of the experiments were carried out preclinical; therefore, clinical trials must be done to confirm their validity. However, the non-targeting effects of exosome inhibitors could be considered as the main issue on exosome biogenesis of healthy cells.

Another fascinating approach that exosomes can be used as a therapeutic agent is the drug delivery potential of them [95–97]. Exosomes from a safe source such as MSCs may be loaded with optional compounds or genetically engineered for targeting infected tissues/cells, suggesting the exosome-based nanocarriers for the treatment of infectious diseases. The advent of safe nanocarriers with high efficiency is the core goal of nanomedicine. However, most of the studies are designed in vitro and animal models; therefore, from a clinical trial application point of view, there are still more questions in the specificity, safety, and proficiency of this method. Moreover, despite various available delivery strategies for therapeutic anti-viral vaccines, therapeutic anti-viral vaccines in humans have been challenging to implement [98]. In another word, these vaccines have not been a strong success so far, and it is certainly valuable to consider more effective adjuvant methods for refining vaccine efficiency. Furthermore, another important thing is the source of immunostimulatory exosomes for human antiviral vaccines which needs more considerations [81]. In a nutshell, researches and explorations in the field of exosomes are in their early stages; therefore, to implement many of the aforementioned ideas, the biology of EVs (especially exosomes) from infected cells must be explored in-depth.

**Conclusion**

Although the exploration of novel specific vaccine for the treatment of SARS-CoV-2 virus pneumonia is critical, it seems to take a long time. Therefore, further research into preventing and controlling the virus is essential as soon as possible. Exosomes from MSCs may be a useful tool for the treatment of SARS-CoV-2 virus pneumonia due to their pivotal roles in the suppression of inflammatory responses and the regeneration of damaged tissues. Furthermore, exosomes may serve as a biomarker, nanocarrier, and vaccine for the treatment of SARS-CoV-2 virus. However, for a better outcome, upcoming efforts are vital to carefully weigh the risk in the use of MSC-Exo for SARS-CoV-2 virus pneumonia against available pre-clinical findings in applicable in vivo models.

**Abbreviations**

ARDS: Acute respiratory distress syndrome; EVs: Extracellular vesicle; FDA: Food and Drug Administration; IP10: Induced protein 10; MCP-1: Monocyte chemoattractant protein-1; MERS: Middle East respiratory syndrome; MSC-Exo: Mesenchymal stem cell-derived exosomes; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; WHO: World Health Organization

**Acknowledgements**

Not applicable.

**Authors’ contributions**

J.R. and A.A. collected the data and edited the manuscript and with equal conceptualization. All authors read and approved the final manuscript.

**Funding**

Not applicable.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors have no competing interests to declare.

Received: 17 June 2020 Revised: 9 July 2020 Accepted: 30 July 2020 Published online: 14 August 2020

References
1. WHO Coronavirus Disease (COVID-19) Dashboard. https://covid19.who.int/. Accessed 8 July 2020.
2. Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, Chiurmezzo D. Covid-19 does not lead to a typical acute respiratory distress syndrome. Am J Respir Crit Care Med. 2020;201:1299–300.
3. Hui DS, IAE, Madani T, Ntoumi F, Koch R, Dar O. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health: the latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020;91:264–6.
4. Abraham A, Krasnodembskaya A. Mesenchymal stem cell-derived extracellular vesicles for the treatment of acute respiratory distress syndrome. Stem Cells Transl Med. 2020;9:28–38.
5. Shah TG, Predescu D, Predescu S. Mesenchymal stem cells-derived extracellular vesicles in acute respiratory distress syndrome: a review of current literature and potential future treatment options. Clin Transl Med. 2019;8:25.
6. Jabbari N, Nawaz M, Rezaie J. Ionizing radiation increases the activity of excitotoxic secretory pathway in MCP-1 human breast cancer cells: a possible way to communicate resistance against radiotherapy. Int J Mol Sci. 2019;20:3649.
7. Martin-Rufino JD, Espinosa-Lara N, Osugui L, Sanchez-Guijo F. Targeting the immune system with mesenchymal stromal cell-derived extracellular vesicles: what is the cargo’s mechanism of action? Front Bioeng Biotechnol. 2019;7:308.
8. Joo HS, Suh JH, Lee HJ, Bang ES, Lee JM. Current knowledge and future perspectives on mesenchymal stem cell-derived exosomes as a new therapeutic agent. Int J Mol Sci. 2020;21:277.
9. Belouzard S, Millet JK, Ucitra BN, Whitkater GR. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses. 2012;4:1011–33.
10. Kuiken T, Foucher RA, Schutter M, Remmelzaan GF, Van Amerongen G, Van Riel D, Laman JD, De Jong T, Van Doornum G, Lim W. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet. 2003;362:263–70.
11. Drosten C, Günther S, Preiser W, Van Der Werf S, Brodt HR, Becker S, Rabanau H, Panning M, Kolesnikova L, Foucher RA. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348:1967–76.
12. de Groot RJ, Baker SC, Baric RS, Brown CS, Drosten C, Enjuanes L, Foucher RA, Galiano M, Gorbalenya AE, Memish ZA. Commentary: Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol. 2013;87:7790–2.
13. Su S, Wang G, Shi W, Liu J, Lai AC, Zhou J, Liu W, Bi Y, Gao GF. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016;24:490–502.
14. Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. New In: Coronaviruses Springer; 2015. p. 1–23.
15. of the International CSG. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5:536.
16. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y, Li B, Huang C-L. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–3.
17. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med. 2020;26:490–2.
18. Whitkater GR, Millet JK. Biochemical characterization of Middle East respiratory syndrome coronavirus spike protein proteolytic processing. New York: In MERS Coronavirus Springer; 2020. p. 21–37.
19. La A, Alzoughool F, Atoum M. The human coronavirus disease COVID-19: its origin, characteristics, and insights into potential drugs and its mechanisms. Pathogens. 2020;9:23.
20. Wu J, Z-Y, N, Hu Y, Liang W-H, Ou C-Q, He J-X, Liu L, Shan H, Lei C-L, Hui DS. Clinical characteristics of coronavirus 2019 in China. N Engl J Med. 2020;382:1708–20.
21. Pung R, Chiew CJ, Young BE, Chin S, Chen M, Clapham HE, Cook AR, Maurer-Stroh S, Toh MP, Poh C. Investigation of three clusters of COVID-19 in Singapore: implications for surveillance and response measures. Lancet. 2020;395:1039–46.
22. Lauer SA, Gratz KH, Qi J, Jones FK, Zheng Q, Meredith HR, Azman AS, Reich NG, Leslier J. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med. 2020;172:577–82.
23. Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H, Yang J, Xing F, Liu J, Yip CC-Y, Poon RW-S. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395:514–23.
24. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X. Clinical features of patients with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
25. Liu Y, Yang Y, Zhang C, Huang F, Fang W, Yuan J, Wang Z, Li J, Li J, Feng C. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020;63:364–74.
26. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–13.
27. Pan Y, Zhang D, Yang P, Poon LL, Wang Q. Viral load of SARS-CoV-2 in clinical samples. Lancet Infect Dis. 2020;20:e411–2.
28. Kim JY, Ko JH, Kim Y, Kim Y-J, Kim J-M, Chung Y-S, Kim HM, Han M-G, Kim SY, Chin SY. Viral load kinetics of SARS-CoV-2 infection in first two patients in Korea. J Korean Med Sci. 2019;35:e86.
29. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, Yu J, Kang M, Song Y, Xia J. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020;382:1177–9.
30. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323:1061–9.
31. Zhang B, Zhou X, Qiu Y, Feng F, Feng J, Jia Y, Zhu H, Hu K, Liu J, Liu Z. Clinical characteristics of 82 death cases with COVID-19. MedRxiv 2020;1:e20205458.
32. Adhikari SP, Meng S, Wu YJ, Mao Y-P, Ye RX-W, Wang Q-Z, Sun C, Sylvia S, Rozelle S, Raat H. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty. 2020;9:1–12.
33. Murthy S, Gomersall CD, Fowler RA. Care for critically ill patients with COVID-19. JAMA. 2020;323:1499–500.
34. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang X, Chen H, Yu H. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130:2620–9.
35. Diao B, Wang C, Tan Y, Chen X, Liu Y, Ling L, Chen L, Li M, Liu Y, Wang G. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol. 2020;11:827.
36. Yang Y, Chen C, Li J, Yuan J, Wei J, Huang F, Wang F, Li G, Li Y, Xing L, Peng L. Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19. J Allergy Clin Immunol. 2020; https://doi.org/10.1016/j.jaci.2020.04.027.
37. Tian S, Hu W, Niu L, Liu H, Xu H, Xiao SY. Pulmonary pathology of early phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol. 2020;15:700–4.
38. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420–2.
39. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020;71:762–8.
40. Park WB, Kwon N-J, Choi S-J, Kang CK, Choe PG, Kim JY, Yun J, Lee G-W, Seong M-W, Kim NJ. Virus isolation from the first patient with SARS-CoV-2 in Korea. J Korean Med Sci. 2019;35:e84.
41. Zhang H, Zhou P, Wei Y, Yue H, Wang Y, Hu M, Zhang S, Cao T, Yang C, Li M. Histopathologic changes and SARS-CoV-2 immunostaining in the lung of a patient with COVID-19. Ann Intern Med. 2020;172:629–32.

42. Fink SL, Cookson BT. Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infect Immun. 2005;73:1907–16.

43. Yang M. Cell pyroptosis, a potential pathogenic mechanism of 2019-nCoV infection. Available at SSRN 3527420; 2020.

44. Rezaei J, Rahbarghazi R, Pezeshki M, Mazhar M, Yekani F, Khakar M, Shokrollahi E, Amini H, Hashemzadeh S, Sokullu SE, Tokac M. Cardioprotective role of extracellular vesicles: a highlight on exosome beneficial effects in cardiovascular diseases. J Cell Physiol. 2019;294:21732–45.

45. Kowal J, Tkach M, Théry C. Biogenesis and secretion of exosomes. Curr Opin Cell Biol. 2014;26:116–25.

46. Jabbari N, Karimpour M, Khakar M, Akbariazadeh A, Heidarzadeh M, Mojarad B, Jabbari N, Karimpour M, Akbariazadeh A, Heidarzadeh M, Mojarad B, Kowal J, Tkach M, Théry C. Biogenesis and secretion of exosomes. Curr Opin Cell Biol. 2014;26:116–25.

47. Kesimer M, Scull M, Brighton B, DeMaria G, Burns K, O.

48. Hannafon BN, Ding W-Q. Intercellular communication by exosome-derived microRNAs in cancer. Int J Mol Sci. 2013;14:2420–69.

49. Han Y, Li X, Zhang T, Han Y, Chang F, Ding J. Mesenchymal stem cells for regenerative medicine. Cells. 2019;8:886.

50. Zhao T, Sun F, Liu J, Ding T, She J, Mao F, Xu W, Qian H, Yan Y. Emerging role of mesenchymal stem cell-derived exosomes in regenerative medicine. Curr Stem Cell Res Ther. 2019;14:482–94.

51. Satija NK, Singh VK, Verma YK, Gupta P, Sharma S, Afrin F, Sharma M, Mohammadipoor A, Antebi B, Batchinsky AI, Cancio LC. Therapeutic potential of products derived from mesenchymal stem/stromal cells in pulmonary disease. Respir Res. 2018;19:218.

52. Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, Shan G, Meng F, Du D, Wang S. Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020;11:216.

53. Rogers TB, Pati S, Gaa S, Riley D, Khakoo AY, Patel S, Wardlow RD II, Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, Shan G, Meng F, Du D, Wang S. Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020;11:216.

54. Jabbari N, Karimpour M, Khakar M, Akbariazadeh A, Heidarzadeh M, Mojarad B, Kowal J, Tkach M, Théry C. Biogenesis and secretion of exosomes. Curr Opin Cell Biol. 2014;26:116–25.

55. Kelemen P, Kelly J, Mathew SG, Bielanski J, Howard D, O'Sullivan D, Bhardwaj N, Chandra A, Rabinovitch RS. Mesenchymal stem cell treatment prevents H9N2 avian influenza virus-induced acute lung injury in mice. Stem Cell Res Ther. 2016;7:159.

56. Kelemen P, Kelly J, Mathew SG, Bielanski J, Howard D, O'Sullivan D, Bhardwaj N, Chandra A, Rabinovitch RS. Mesenchymal stem cell treatment prevents H9N2 avian influenza virus-induced acute lung injury in mice. Stem Cell Res Ther. 2016;7:159.

57. Kelemen P, Kelly J, Mathew SG, Bielanski J, Howard D, O'Sullivan D, Bhardwaj N, Chandra A, Rabinovitch RS. Mesenchymal stem cell treatment prevents H9N2 avian influenza virus-induced acute lung injury in mice. Stem Cell Res Ther. 2016;7:159.

58. Kelemen P, Kelly J, Mathew SG, Bielanski J, Howard D, O'Sullivan D, Bhardwaj N, Chandra A, Rabinovitch RS. Mesenchymal stem cell treatment prevents H9N2 avian influenza virus-induced acute lung injury in mice. Stem Cell Res Ther. 2016;7:159.

59. Kelemen P, Kelly J, Mathew SG, Bielanski J, Howard D, O'Sullivan D, Bhardwaj N, Chandra A, Rabinovitch RS. Mesenchymal stem cell treatment prevents H9N2 avian influenza virus-induced acute lung injury in mice. Stem Cell Res Ther. 2016;7:159.

60. Kelemen P, Kelly J, Mathew SG, Bielanski J, Howard D, O'Sullivan D, Bhardwaj N, Chandra A, Rabinovitch RS. Mesenchymal stem cell treatment prevents H9N2 avian influenza virus-induced acute lung injury in mice. Stem Cell Res Ther. 2016;7:159.

61. Kelemen P, Kelly J, Mathew SG, Bielanski J, Howard D, O'Sullivan D, Bhardwaj N, Chandra A, Rabinovitch RS. Mesenchymal stem cell treatment prevents H9N2 avian influenza virus-induced acute lung injury in mice. Stem Cell Res Ther. 2016;7:159.

62. Kelemen P, Kelly J, Mathew SG, Bielanski J, Howard D, O'Sullivan D, Bhardwaj N, Chandra A, Rabinovitch RS. Mesenchymal stem cell treatment prevents H9N2 avian influenza virus-induced acute lung injury in mice. Stem Cell Res Ther. 2016;7:159.
requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles: Taylor & Francis. J Extracell Vesicles. 2014;3:26913.

85. Théry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, Antoniou A, Arab T, Archer F, Akin-Smith GK. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7:1535750.

86. Yu B, Zhang X, Li X. Exosomes derived from mesenchymal stem cells. Int J Mol Sci. 2014;15:4142–57.

87. Teixeira FG, Carvalho MM, Sousa N, Salgado AJ. Mesenchymal stem cells secretome: a new paradigm for central nervous system regeneration? Cell Mol Life Sci. 2013;70:3871–82.

88. Zhang ZG, Buller B, Chopp M. Exosomes—beyond stem cells for restorative therapy in stroke and neurological injury. Nat Rev Neurol. 2019;15:193–203.

89. Phinney DG. Functional heterogeneity of mesenchymal stem cells: implications for cell therapy. J Cell Biochem. 2012;113:2806–12.

90. Radtke S, Görgens A, Liu B, Horn PA, Giebel B. Human mesenchymal and murine stromal cells support human lympho-myeloid progenitor expansion but not maintenance of multipotent haematopoietic stem and progenitor cells. Cell Cycle. 2016;15:540–5.

91. Kordelas L, Rebmann V, Ludwig A, Radtke S, Ruesing J, Doeppner T, Apple M, Horn P, Beelien D, Giebel B. MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease. Leukemia. 2014;28:970–3.

92. Huang R, Qin C, Wang J, Hu Y, Zheng G, Qiu G, Ge M, Tao H, Shu Q, Xu J. Differential effects of extracellular vesicles from aging and young mesenchymal stem cells in acute lung injury. Aging (Albany). 2019;11:7996.

93. Arslan F, Lai RC, Smeets MB, Akeroyd L, Choo A, Aguor EN, Timmers L, van Rijen HV, Doevendans PA, Pastekamp G. Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury. Stem Cell Res. 2013;10:301–12.

94. Catalano M, O’Driscoll L. Inhibiting extracellular vesicles formation and release: a review of EV inhibitors. J Extracell Vesicles. 2020;9:1703244.

95. Lv L-H, Wan Y-L, Lin Y, Zhang W, Yang M, Li G-L, Lin H-M, Zhang C-Z, Chen Y-J, Min J. Anticancer drugs cause release of exosomes with heat shock proteins from human hepatocellular carcinoma cells that elicit effective natural killer cell antitumor responses in vitro. J Biol Chem. 2012;287:15874–85.

96. Gneche M, He H, Noiseux N, Liang OD, Zhang L, Morello F, Mu H, Melo LG, Pratt RE, Ingwall JS. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J. 2006;20:661–9.

97. Lamichhane TN, Jayaram A, Patel DB, Parajuli B, Livingston NK, Arumugagaamy N, Schardt JS, Jay SM. Oncogene knockdown via active loading of small RNAs into extracellular vesicles by sonication. Cell Mol Bioeng. 2016;9:315–24.

98. Hung C-F, Ma B, Monie A, Tsen S-W, Wu TC. Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin Biol Ther. 2008;8:421–39.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.